ZTSZoetis

$73.60

The financials

Zoetis by the numbers

Zoetis (ZTS) reported revenue of $2.47B in Q2 2026 (quarter ended Jun 30, 2026), down 0.2% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $691M (28% of revenue). For the full year FY2025, revenue was $9.47B (+2.3% year on year) and net income $2.67B. Its largest product in Q2 2026 was Dermatology at $398M, 17.5% of the disclosed total, just ahead of Cattle at 17.1%.

Zoetis income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Revenue$2.47B$2.47B−0.2%
Gross profit$1.79B$1.81B−0.8%
Net income$691M$726M−4.8%
Diluted EPS$1.65$1.63+1.2%
Revenue by product, Q2 2026, as reported to the SEC
ProductRevenueShare
Dermatology$398M17%
Cattle$390M17%
Anti Infective Products$244M11%
Livestock$222M9.8%
Pain Sedation$217M9.5%
Other Pharmaceuticals$168M7.4%
Animal Health Diagnostics$123M5.4%
Swine$117M5.1%
Poultry$115M5.1%
Fish$83M3.6%
Horses$74M3.3%
Other Non Pharmaceuticals$70M3.1%
Contract Manufacturingand Human Health Diagnostics$29M1.3%
Manufactured Product Other$26M1.1%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Q2 2026Total $2.28B (+4.5%)
Livestock grew +23% year on yearDermatology -16% year on year
  • Dermatology$398.0MQoQ +14%year on year -16%
  • Cattle$390.0MQoQ -0.51%year on year +21%
  • Anti Infective Products$244.0MQoQ +1.2%year on year +9.9%
  • Livestock$222.0MQoQ -1.3%year on year +23%
  • Pain Sedation$217.0MQoQ +6.9%year on year -2.7%
  • Other Pharmaceuticals$168.0MQoQ +6.3%year on year -4.0%
  • Animal Health Diagnostics$123.0MQoQ +5.1%year on year +12%
  • Swine$117.0MQoQ -4.9%year on year -0.85%
  • Poultry$115.0MQoQ -2.5%year on year +11%
  • Fish$83.0MQoQ +26%year on year +2.5%
  • Horses$74.0MQoQ -2.6%year on year +4.2%
  • Other Non Pharmaceuticals$70.0MQoQ +6.1%year on year +2.9%
  • Contract Manufacturing and Human Health Diagnostics$29.0MQoQ +26%year on year -12%
  • Manufactured Product Other$26.0MQoQ +24%year on year +4.0%
Segment sum = 92% of reported consolidated revenue · Latest source: 10-Q filed 2026-08-06, SEC EDGAR